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Campylobacter infection is one of the most common causes of bacterial gastroenteritis
worldwide and a major global health threat due to the rapid development of antibiotic
resistance. Currently, there are no vaccines approved to prevent campylobacteriosis,
and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the
main antibody class found in mucous secretions, including human milk, and serves as
the first line of defense for the gastrointestinal epithelium against enteric pathogens. In
this study, we describe the prophylactic activity of orally delivered recombinant SIgA
generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their
reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility
and highly conserved across Campylobacter species associated with severe enteritis. In
an immunocompetent weaned mouse model, a single oral administration of FliD-reactive
SIgA CAA1 or CCG4 at 2 h before infection significantly enhances Campylobacter
clearance at early stages post-infection, reducing the levels of inflammation markers
associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the
cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and
CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA
format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a
comparable protective effect. Our work emphasizes the potential of FliD as a target for the
development of vaccines and supports the concept that orally administered FliD-reactive
SIgA can be developed to prevent or mitigate the severity of Campylobacter infections
as well as the development of post-infection syndromes.
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INTRODUCTION
Campylobacter is an established cause of diarrhea worldwide
and has recently been added to the WHO list of bacteria
whose antibiotic resistance might pose a global threat to
human health (1). Campylobacter’s epidemiology differs between
high-income countries, where infections are sporadic, and
low- and middle-income countries, in which the infection
is common in early childhood and a major cause of life-
threatening acute watery diarrhea in infants (2). Considered as
a leading zoonosis, Campylobacter infection is mainly associated
with the consumption of contaminated undercooked animal
meat (poultry being the primary bacteria reservoir), water, or
unpasteurized milk (3).
Campylobacter jejuni and Campylobacter coli are the major
causes of Campylobacter enteritis in humans, and despite the
clinical relevance of other emerging species (4), they will
unlikely be eclipsed in terms of prevalence and magnitude
of the disease. Campylobacteriosis typically results in an
acute, gastrointestinal illness characterized by watery or bloody
diarrhea, fever, weight loss, and cramps that last on average
6 days (3, 5). Although considered a self-limiting disease,
the severe dehydration associated with Campylobacter enteritis
represents a significant cause of death among newborns and
children particularly in developing countries (6). Furthermore,
C. jejuni infections has been consistently linked with the onset of
autoimmune conditions such as Guillain–Barré syndrome (GBS)
(7, 8) and inflammatory bowel disease (IBD) (9).
Despite a yet incomplete understanding of Campylobacter
pathogenesis, flagellum-mediated motility is widely presumed
pivotal for virulence and pathogenicity, as demonstrated in both
experimental animal models and in human healthy volunteer
studies (10). Nevertheless, flagellin (FlaA), the major constituent
of the flagellum, is not highly conserved even within the same C.
jejuni species, and its heavy glycosylation pattern varies greatly
depending on the strain and growth phase (11, 12). In addition,
a recombinant non-glycosylated form of C. jejuni flagellin was
shown to be poorly immunogenic in clinical trials (2). Moreover,
the possibility to use C. jejuni as vaccines has been limited by the
risk of GBS development associated with ganglioside mimicry of
bacterial lipo-oligosaccharide (LOS) (2).
Due to these shortcomings, there are currently no vaccines
approved to prevent Campylobacter infection. Rehydration
is the main form of therapy, and albeit antibiotics have
been shown to be beneficial in severe infections, they are
often not recommended due to the rapid development of
antibiotic resistance (1). Despite recovering from infection,
continuous exposure of infants in low-income countries
to intestinal pathogens, including Campylobacter, has been
linked to environmental enteropathy (EE)/environmental enteric
dysfunction (EED), a subclinical chronic inflammation of
the small intestine. This inflammation is associated with
malabsorption of nutrients, growth faltering, impaired cognitive
development, changes inmicrobiota, and reduced responsiveness
to oral vaccination (13).
Secretory immunoglobulin A (SIgA) represents the most
abundant class of antibodies produced in humans and serves
as the first line of defense at the level of intestinal mucosa
against enteric toxins and pathogens (14). Typically, a SIgA
consists of two monomeric IgA linked tail to tail by disulfide
bonds via a 15-kDa protein called joining (J) chain and further
complexed with a heavily glycosylated secretory component (SC)
(15). While IgA monomers and the J chain are synthesized,
assembled, and secreted by plasma cells in the lamina propria, the
SC consists of the ectodomain of the polymeric immunoglobulin
receptor (pIgR) that remains bound to polymeric IgA (pIgA)
following transcytosis across the enterocyte (16). The SC
protects the antibody from proteolytic degradation, confers
innate recognition functions, and contributes to appropriate
tissue localization by anchoring the immunoglobulin to the
mucus lining the epithelial surface (17, 18). SIgA acts primarily
by preventing adhesion of pathogens to epithelial cells through
receptor blockade, steric hindrance, and/or immune exclusion,
eventually facilitating their clearance from the intestinal lumen
via peristaltic and mucociliary activities (14, 19). Furthermore,
antigen-bound SIgA can be transported back into Peyer’s
patches (PPs) subepithelial dome (SED) by microfold (M) cells
in a process known as reverse transcytosis, which promotes
migration and activation of follicular DCs, thus conditioning
the inflammatory response associated to infection by enteric
pathogens (14, 20). SIgA is also the main antibody class found
in mucous secretions, including human milk, in which the Ig
portion of the molecule is produced by mammary gland plasma
cells that originate in the small intestine (entero-mammary
pathway) (21). The provision of SIgA by breastfeeding has been
reported to be critical for the protection against enteric pathogens
especially in early infancy, when the contribution of endogenous
production is limited (22–24).
In this study, an immunocompetent mouse model of
Campylobacter infection was used to evaluated the prophylactic
activity of orally delivered recombinant SIgA generated from
human monoclonal antibodies isolated and selected for their
reactivity against the flagellar-capping protein FliD, which is
pivotal for bacteria motility (25), and highly conserved across
Campylobacter species frequently associated with severe neonatal
enteritis (26). We demonstrated that, regardless of the IgA
isotype, prophylactically administered FliD-reactive SIgA can
enhance Campylobacter clearance at early stages post-infection,
dramatically reducing the levels of inflammation markers
associated with epithelial damage and polymorphonuclear
(PMN) cells infiltration. Our data indicate that the prophylactic
activity of these antibodies is not only dependent on the
specificity to FliD but also on features strictly associated with the
SIgA format as the IgG versions of the same antibodies did not
produce a comparable beneficial effect.
MATERIALS AND METHODS
Production of Recombinant FliD Antigen
FliD amino acid sequences from C. jejuni (n = 38) and C. coli
(n = 17) isolates were retrieved from GenBank and aligned
using MEGA software to obtain a consensus sequence. Condon
optimization and synthesis of the corresponding nucleotide
sequence was outsourced (Genscript), and the construct was
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subcloned in pET21a in frame with the C-term His tag. The
plasmid was transformed to Escherichia coli Rosetta strain. Gene
expression was induced by the addition of 1mM isopropyl-beta-
D- thiogalactopyranoside (IPTG) to log-phase grown bacteria.
After 5 h of induction at 37◦C, bacteria were collected by
centrifugation and stored at −20◦C for 16 h before being
resuspended in sonication buffer (50mM NaH2PO4, 300mM
NaCl, 10mM imidazole, and pH 7.4) and being sonicated 4 ×
30 s in ice. Lysed bacteria were spun (14,000 × g, 1 h, and 4◦C),
and the supernatants were filtered and then loaded on a nickel
column (HiTrap Chelating HP, GE HealthCare). Column was
washed with washing buffer (50mM NaH2PO4, 300mM NaCl,
10mM imidazole, and pH 7.4) followed bywashing buffer+ 0.1%
Triton-X114 and washing buffer again. Bound protein was eluted
from the column with elution buffer (50mMNaH2PO4, 300mM
NaCl, 500mM imidazole, and pH 7.4) and dialyzed for 16 h at
4◦C inDulbecco’s phosphate-buffered saline (DPBS). Protein size
was measure on size exclusion column (HiLoad 16/600 Superdex
75 pg; GE Healthcare), and the concentration was measured
before storage at−20◦C.
Isolation of FliD-Reactive Memory B Cells
and Generation of Recombinant mAbs
FliD-reactive monoclonal antibodies CAA1 and CCG4 were
isolated, as previously described (27, 28), from IgA+ and IgG+
memory B cells derived from tonsillar donors who had given
written informed consent, following approval by the Cantonal
Ethical Committee of Cantone Ticino, Switzerland (CE3536
2019-02061). The sequences for the variable regions of the
mAbs were obtained from memory B cell clone messenger
RNAs (mRNAs) following reverse transcription PCR (RT-PCR)
and sequencing. The VH region of each mAb was cloned into
a plasmid encoding IgA1, IgA2 allotype m(2) (29), or IgG1
heavy chains. The constructs were transiently transfected in
Expi293 cells together with those for the corresponding light
chains and, in the case of SIgA, also with those encoding
for the joining chain (J) and the ectodomain of pIgR (SC)
(29). After 48 h, cells were supplemented with supplement
medium and further incubated for 5 days under shaking.
Next, cells were spun down, and the supernatant was filtered
before being purified using CaptureSelectTM IgA Affinity Matrix
(Thermo Fisher). SIgA assembly was appraised by ultrahigh
performance liquid (UHPL) chromatography using ACQUITY
BEH SEC Guard Column (Waters) and by denaturing non-
reducing gel using SIgA purified from human milk (MP
Biomedicals) as positive control. The purified immunoglobulins
were quantified with PierceTM Rapid Gold BCA Protein
Assay Kit (Life Technologies) and then aliquoted and store
at−80◦C.
N-Glycan Oligosaccharide and Total
Carbohydrate Analysis
N-Glycan oligosaccharide analysis was performed as previously
described (30). Briefly, a GlycoWorks RapiFluor-MS N-Glycan
Kit (Waters Corporation, Milford, MA) was used to identify
and quantify N-linked glycans following the manufacturer’s
instructions. Fluor-MS N-glycan analysis was performed using
an Agilent 1,260 Infinity II HPLC system equipped with a
1,260 FLD detector (Agilent, Santa Clara, CA) and an Agilent
6,230 electrospray ionization time-of-flight mass spectrometer
(Agilent, Santa Clara, CA). A HILIC AdvanceBio Glycan
Mapping column (120 Å, 2.1 × 150mm, 2.7µm), operated at
45◦C, was used to separate various N-glycans. Fifty microliters
of prepared samples was injected into liquid chromatography–
mass spectrometry (LC-MS) system, with a flowrate of 0.6
mg/ml and a gradient run time of 55min. Fluorescence was
obtained using excitation and emission wavelengths of 265
and 425 nm, respectively. MS was acquired simultaneously
from 400 to 2,000 m/z at a constant scan rate of one
spectrum per second. N-Glycans were assigned based on
m/z values using the N-glycan Glycobase database, and N-
glycan quantification was calculated on integration of the
fluorescence chromatogram.
Total carbohydrate analysis was performed as previously
described (30). Briefly, a glycoprotein carbohydrate estimation
kit (Thermo-Fisher #23260) was used to determine the total
carbohydrate content (both N- and O-linked oligosaccharides)
in mAb samples as a percentage of total protein mass. Lysozyme,
bovine serum albumin (BSA), ovalbumin, Apo-transferrin,
fetuin, and α1-acid glycoprotein were used as glycoprotein
standards to construct a standard curve.
Size Exclusion Chromatography and
Sedimentation Velocity Analytical
Ultracentrifugation
Size exclusion chromatography (SEC) was performed as
previously described (30). Briefly, a Shimadzu Prominence
ultrafast liquid chromatography HPLC system equipped with a
diode array detector (with absorbance detection at 214 nm) was
equilibrated at 0.5 ml/min flowrate in 0.2M sodium phosphate
buffer, pH 6.8 for at least 2 h. Ten microliters of each mAb (10 µg
total protein) was injected and separated by a TOSOH TSKgel
G4000SWXL column (8µm particle size, 7.8mm ID × 30 cm)
with the corresponding guard column operated at ambient
temperature (Tosoh Biosciences) using a 30-min run time. Gel
filtration molecular weight standards (Bio-Rad, Hercules, CA)
were injected before and after the mAb samples to ensure
integrity of the column and HPLC system. Potential presence of
larger aggregates was determined by running mAb samples with
and without the SEC column (i.e., protein percentage recovery).
Data were analyzed using LC-Solution software (Shimadzu,
Kyoto, Japan).
Sedimentation velocity analytical ultracentrifugation (SV-
AUC) was performed as described previously (30) using a
Proteome Lab XL-I (Beckman Coulter) analytical ultracentrifuge
equipped with a scanning ultraviolet–visible optical system.
All experiments were performed at 20◦C after at least 1 h
of equilibration after the rotor reached 20◦C. SV-AUC was
performed at a rotor speed of 40,000 rpm and with detection at
280 nm. The data were analyzed using Sedfit software (Dr. Peter
Schuck, NIH).
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Intrinsic Fluorescence Spectroscopy and
Relative Solubility Measurements
Intrinsic tryptophan fluorescence spectroscopy measurements as
a function of temperature and polyethylene glycol (PEG) relative
solubility measurements were both performed as described
previously (30). For fluorescence spectroscopy measurements,
20 µl of each mAb sample was diluted to 0.2 mg/ml in PBS,
pH 7.2 and loaded into a 384-well plate (Hard-Shell 384-well
PCR plates) and overlaid with 2 µl of silicon oil (Thermo
Fisher Scientific,Waltham,MA). Samples were excited at 295 nm,
and the emission spectra were recorded from 300 to 450 nm
with an integration time of 100ms using a fluorescence plate
reader equipped with a charge-coupled device (CCD) detector
(Fluorescence Innovations, Minneapolis, MN). Temperature
ramps were programmed from 10 to 100◦C with an increment of
2.5◦C per step. The mean center of spectra mass peak algorithm
was used to analyze the data to determine the shift in fluorescence
peak position as a function of temperature. With respect to
relative solubility measurements, various concentrations of PEG
10,000 solutions ranging from 0 to 25% w/v were prepared with
a final mAb concentration of 0.2 mg/ml. Samples were incubated
overnight at room temperature in the dark in 384-well plates with
30 µl in each well. The next day, the plates were centrifuged for
15min at ∼1,200×g, and the supernatant was transferred to a
clean 384-well plate. Relative protein concentration in each well
was thenmeasured at 214 nm using a SpectramaxM5 plate reader
(Molecular devices). Thermal melting temperature values (Tm)
and % PEG midpoint calculations were performed using Origin
v 9.1 software (OriginLab, Northampton, MA).
Binding to Recombinant FliD: ELISA,
Western Blot, and BLI Epitope Binning
Quantification of recombinant SIgA and IgG by ELISA was
performed by coating 96-well plates with goat anti-human IgA
or IgG (SouthernBiotech). Two-fold serial dilutions of the mAbs
in duplicates were incubated for 1 h at room temperature.
In the case of SIgA, detection was performed using human
pIgR biotinylated antibody biotinylated anti-human SC antibody
(R&D System) followed by incubation with streptavidin-AP,
while goat anti-human IgG-AP (SouthernBiotech) was used for
IgG. SIgA purified from human milk (MP Biomedicals) and
Rituximab (MabThera) were used as quantification standards for
SIgA and IgG, respectively.
Binding of CAA1, CCG4 SIgA, and IgG counterparts to
the recombinant antigen was measured by ELISA using FliD-
coated 96-well-plates following the same detection protocol
described above.
Epitope binning was tested by biolayer interferometry (BLI)
using Octet Red96 (ForteBio) immobilizing recombinant FliD
antigen (5µg/ml) onto APS Biosensor (Pall ForteBio) for 7min.
After incubation with blocking buffer (BB), the sensor was
incubated with CAA1 SIgA2 (7.5µg/ml) for 7min before being
further incubated with CCG4 SIgA2, CAA1 SIgA2, or BB for
additional 7 min.
Binding of SIgA2 to FliD antigen in denaturing and reducing
conditions was tested by Western blot. Briefly, 5 µg of
recombinant FliD was loaded on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) NuPAGE 12%
Bis–Tris protein gel (Thermo Fisher Scientific) in the presence of
a reducing agent. Blotting was performed using IBLOT SYSTEM
(Invitrogen), and the membrane was blocked with 5% milk
(Biorad) in Tris-buffered saline with Tween 20 (TBST) for 1 h
at room temperature (RT). The mAbs were biotinylated by
incubation with 20mM biotin using the EZ-Link NHS-PEO
Solid Phase Biotinylation Kit followed by desalting with Zeba
Spin Desalting Columns (Thermo Scientific). The membrane
was incubated with a 1% blocking grade blocker (BioRad) in
TBST containing 20µg/ml of biotinylated mAbs followed by
washes in TBST and by incubation with streptavidin-horseradish
peroxidase (HRP). Detection was performed using ECL detection
kit (GE Healthcare) on Fusion Fx7 (Witec AG).
Sensitivity to IgAse was evaluate by incubating CAA1 SIgA1
and SIgA2 with recombinant IgA protease from Neisseria
gonorrhoeae (IgAse Pro-Pro-Y-Pro- Mo Bi Tec). Briefly, 100 µg
of CAA1 SIgA1 and SIgA2 were incubated at 37◦C for 18 h with
1.5µg of IgAse or with reaction buffer alone. The post-incubation
products were visualized in a denaturing non-reducing gel with
HiMark Prestained Protein Standard (Thermo Fisher).
Bacterial Strains and Growth Conditions
C. jejuni 81-176 and C. coli NCTC 11437 strains were purchased
from the American Type Culture Collection (ATCC) and
Public Health England bacteria collection, respectively. The
Campylobacter species were grown from glycerol stocks in
Mueller–Hinton agar (Sigma Aldrich) (15 g/L) supplemented
with vancomycin and trimethoprim (10µg/ml) (Sigma-
Aldrich) for 96 h at 40◦C in microaerophilic jar with OxoidTM
CampyGenTM 2.5 L Sachet (Fisher Scientific).
Determination of mAb Binding to
Campylobacter Flagellar-Capping Protein
by Flow Cytometry and Microscopy
In vitro binding of the different FliD-reactive SIgA to a pure
culture of C. jejuni was measured by flow cytometry. Fifty
microliters of each mAbs (20µg/ml) was incubated with 50 µl
of C. jejuni 81-176 (107 CFU/ml) for 1 h at 4◦C. After washing
with PBS 2% fetal bovine serum (FBS), bacteria were incubated
for 30min with biotin-conjugated anti-human IgA (Southern
Biotech, Cat. No. 2050-08). Immunoglobulin-bound bacteria
were then stained with streptavidin-PB at 4◦C for 30min.
Samples were washed with PBS 2% FBS, resuspended in 2%
paraformaldehyde and acquired on LSR Fortessa flow cytometer
(BD Biosciences, Franklin Lakes NJ, USA) using forward scatter
(FCS) and side scatter (SSC) parameters in logarithmic mode.
Data were analyzed using the FlowJo software (TreeStar, Ashland,
OR, USA) or FACS Diva software (BD Biosciences, Franklin
Lakes NJ, USA).
Binding of CAA1 and CCG4 SIgA on the poles of C.
jejuni was also confirmed by microscopy. Briefly, 30 µg of
CAA1, CCG4, and HGN194 SIgA2 were incubated with 106
CFU of C. jejuni 81-176 for 1 h at 37◦C in microaerophilic
conditions. Next, bacteria–mAbs complexes were washed and
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further incubated with antihuman IgA–AF647 conjugated (1:200,
Jackson ImmunoResearch, Cat. No. 109-606-011) and SytoBC
(1:1,000, Thermo Fisher Scientific, Cat. No. S34855) for
additional 30min before being poured in microscope slides.
Images were acquired with a Leica SP5 laser scanning confocal
microscope with a 488- and 633-nm excitation. The resulting
fluorescence emission was collected using 490–627-nm (for
SYTOX Green) and 636–770 nm (for Alexa 647) windows.
Samples were imaged with a 63× objective (N.A. 1.4) in xy optical
sections of 61.51µm (1,024 × 1,024 pixels) with a pixel size of
60.1 nm. To improve lateral resolution, the pinhole was set to
0.5 AU.
Mice
Animal experiments were performed in accordance with the
Swiss Federal Veterinary Office guidelines and authorized
by the Cantonal Veterinary Office (TI-09-2019). Twenty-
one-day-old C57BL/6 female mice were purchased from
Charles River Laboratories. Mice were housed, five per cage,
under standardized conditions (20 ± 2◦C, 55 ± 8% relative
humidity, 12 h light/dark cycle), at the Institute for Research in
Biomedicine. Food and water were available ad-libitum, andmice
were monitored daily.
Analysis of mAbs-Specific Binding and
Cross-Reactivity With the Murine
Microbiota in Fecal Samples
In order to measure C. jejuni specific antibody binding to the
mouse microbiota, stools were collected and homogenized in
sterile PBS (0.01 g of stools in 100 µl PBS). Samples were
centrifuged for 5min at 400 g to pellet large debris, and then,
the supernatant were centrifuged at 8,000 g for 5min to pellet
bacteria. The supernatant was removed, and the bacterial pellet
was resuspended in 150 µl (50µg/ml) of the different anti-
Campylo mAbs and incubated at 4◦C for 30min. After washing,
bacteria were incubated at 4◦C for 30min with biotin-conjugated
anti-human IgA (Southern Biotech, Cat. No. 2050-08) and SYTO
BC (1:1,000, Thermo Fisher Scientific, Cat. No. S34855). Bacteria
were washed once and then incubated with streptavidin-PB and,
at the end, resuspended in 2% paraformaldehyde in PBS for
flowcytometry analysis. All the samples were acquired on an
LSR Fortessa flow cytometer (BD Biosciences, Franklin Lakes NJ,
USA) using FCS and SSC parameters in logarithmic mode. Data
were analyzed using the FlowJo software (TreeStar, Ashland, OR,
USA) or FACS Diva software (BD Biosciences, Franklin Lakes
NJ, USA).
mAbs Localization and Persistence in the
Weaned Mice Intestinal Tract
Differences in localization and persistence of SIgA vs. IgG
in the gastrointestinal (GI) tract of 21-day-old C57BL/6 mice
were evaluated by testing the PK of the two species in the
three GI subcompartments: small intestine, cecum, and colon.
Weaned mice were administered with a PBS solution containing
150 µg of Campylobacter-irrelevant antibody HGN194, which
targets HIV gp120 and presents no cross-reactivity with the
murine microbiota, in the form of SIgA2m(2) or IgG. A control
group was administered only with PBS. At 2, 4, and 8 h post-
oral administration, five animals per group were euthanized,
and the content of the three different intestinal tracts was
collected and resuspended in 1.5ml PBS. The samples were then
homogenized, and after centrifugation, the supernatants were
collected and stored at −20◦C. The detection of human IgA
or IgG in the different parts of the GI tract was performed
by ELISA. Briefly, 96-well plates were coated with goat anti-
human IgA or IgG antibodies (Southern Biotechnology: 2050-01
and 2040-01) and blocked with 1% BSA blocking buffer. Plates
were then incubated with 2-fold serial dilutions (1:2 to 1:256)
of each intestinal sample for 1 h at room temperature. After
four washes with PBS + 0.05% Tween 20, the presence of the
antibodies was detected by incubation with goat anti-human
lambda antibody AP conjugated (Southern Biotechnology: 2070-
04) for 1 h at room temperature followed by 15min incubation
with p-nitrophenylphosphate (pNPP) and detection at 405 nm.
Taking into account the different numbers of lambda light chains
possessed by the polymeric immunoglobulin, to quantify the
amount of SIgA or IgG in the samples, two distinct standard
curves were built using HGN194 SIgA and HGN194 IgG as
standards, respectively. No signals were detected testing the
samples from the control animals administered only with PBS.
Oral Prophylaxis and Infection Protocol
C57BL/6 female mice (21 days old) were pre-treated with 10mg
of vancomycin (Sigma-Aldrich) in 200 µl PBS 48, 24, and 12 h
prior to mAbs administration. Mice were orally administered
with 200µg of FliD-reactive mAbs in 200µl PBS 2 h before being
infected by oral gavage with C. jejuni 81-176 (108 CFU/200 µl
PBS). In order to monitor the prophylactic efficacy, mice were
observed daily, and stools were collected at 24, 48, and 72 h post-
infection. Tomonitor the pathogen load, stools were resuspended
and plated onMueller–Hinton agar plates containing 10µg/ml of
vancomycin and trimethoprim.
Flow Cytometry Analysis of Cecum Lamina
Propria PMNs
Mice were sacrificed 72 h post-infection; the cecumwas removed,
opened longitudinally, delicately separated by cecal content, and
washed twice with ice-cold PBS. The cecum was digested at
37◦C for 30min with Roswell Park Memorial Institute (RPMI)
added with 5mM ethylenediaminetetraacetic acid (EDTA) for
two times. The filtrated fragments were then digested in
RPMI 5% FBS, 1 mg/ml collagenase type II, and 40µg/ml
DNase-I for 40min. The filtered suspension, containing the
cecum lamina propria cells, was centrifuged for 5min at 1,500
rpm and resuspended in RPMI complete medium. Single-cell
suspensions from cecal lamina propria were stained with labeled
antibodies diluted in PBS with 2% FBS for 20min on ice. The
following mouse antibodies (mAbs) were used for experiments:
APC-conjugated anti-CD11b (1:200) and PE-conjugated anti-
GR1 (1:200). Samples were acquired on an LSR Fortessa (BD
Biosciences, Franklin Lakes NJ, USA) flow cytometer. Data were
analyzed using FlowJo software (TreeStar, Ashland, OR, USA) or
FACS Diva software (BD Biosciences, Franklin Lakes NJ, USA).
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Quantification of Fecal Lipocalin-2
The inflammation status of mice was evaluated by measuring
the levels of lipocalin-2 (LCN-2) in fecal supernatants via
ELISA assay (R&D systems, DuoSet ELISA Mouse Lipocalin-
2/NGAL) 24, 48, and 72 h post-infection. Briefly, 0.01 g feces
was resuspended in 100 µl in PBS, centrifuged for 10min at
maximum speed, and diluted before performing the ELISA assay,
according to manufacturer’s instructions.
Quantification of Fecal IgA by ELISA
ELISA plates were coated (16 h at 4◦C) with 75 µl of unlabeled
goat anti-murine IgA (Southern Biotech) at 5µg/ml in PBS,
washed four times with PBS 0.025% Tween 20, and saturated
with 200 µl of PBS 10% fetal calf serum (FCS) for 2 h at room
temperature. Fifty microliters of serial dilutions of stools was
incubated for 4 h at room temperature. After four washes in PBS
0.025% Tween 20, 50 µl of alkaline-phosphatase-conjugated goat
anti-mouse IgA (Southern Biotech) (1/500 in PBS 10% FCS) were
added and plates incubated for 2 h at room temperature. The
assay was developed with Sigma 104 phosphatase substrate.
Histological Evaluation of C. jejuni
Infections
Ceca from all animals were examined at necropsy, fixed in 10%
neutral buffered formalin for at least 48 h prior to embedding
in paraffin, and stained with hematoxylin and eosin (H&E).
Pathological scores were determined in a blinded manner
using a previously described scoring scheme (31). Briefly, each
tissue section was assessed for (1) submucosal edema (0, no
change; 1, mild; 2, moderate; 3, severe); (2) crypt hyperplasia
(0, no change; 1, 1–50%; 2, 51–100%; 3, >100%); (3) goblet
cell depletion (0, no change; 1, mild depletion; 2, severe
depletion; 3, absence of goblet cells); (4) epithelial integrity [0,
no pathological changes detectable; 1, epithelial desquamation
(few cells sloughed, surface rippled); 2, erosion of epithelial
surface (epithelial surface rippled, damaged); 3, epithelial surface
severely disrupted/damaged, large amounts of cell sloughing;
4, ulceration [with an additional score of 1 added for each
25% fraction of tissue in the cross-section affected up to a
maximum score of 8 (4 + 4) for a tissue section that had entirely
lost its crypt structure due to epithelial cell loss and immune
cell infiltration]; (5) mucosal mononuclear cell infiltration (per
400× magnification field) (0, no change; 1, <20; 2, 20–50; 3,
>50 cells/field); (6) submucosal PMN and mononuclear cell
infiltration (per 400× magnification field) (1, <5; 2, 21–60; 3,
61–100; 4, >100 cells/field). A maximum score under this scale
is 24.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism v7.04
(GraphPad Software, La Jolla, CA, USA). Mann–Whitney U test
was used to determine the statistical significance of the results. A
p < 0.05 was considered significant in all cases.
RESULTS
Isolation of FliD-Reactive Monoclonal
Antibodies
Different Campylobacter’s proteins were evaluated as potential
targets to prevent infection on the basis of (i) the presence of
surface exposed epitopes, (ii) role in the bacteria pathogenesis,
(iii) ability to stimulate an immune response in the context
of natural infection, and (iv) level of amino acid sequence
conservation within but not limited to the C. jejuni species.
The flagellar-capping protein FliD, also known as hook-
associated protein 2 (HAP2), is a 70-kDa protein with
high sequence conservation across the C. jejuni species (26)
(Supplemental Figures 1A,B). Based on structures and self-
oligomerization mechanisms characterized for other flagellated
pathogens (25, 32), Campylobacter FliD oligomers form the cap
protein complex located at the tip of the flagellum, which controls
the distal growth of the filament by regulating the assembly of
the flagellin molecules. Due to its functional role in filament
elongation, FliD-deficient mutants exhibit defects in bacterial
motility (25). The potential of FliD as a promising target is
strengthened by the proposed involvement in cell adherence (33)
and the immunogenicity in chickens during natural infection.
Accordingly, it has been suggested as a vaccine candidate for
the prevention C. jejuni in broilers (26, 34). FliD was therefore
selected as a candidate target antigen for monoclonal antibody
(mAb) development.
The frequencies of IgG+ and IgA+ FliD-reactive memory B
cells in 50 tonsillar samples of Swiss origin were evaluated using
the antigen-specific memory B cell repertoire analysis (AMBRA)
(35) (Supplemental Figure 2). IgG+ and IgA+ memory B cells
from selected tonsils were then immortalized under clonal
conditions (28), and culture supernatants were screened using a
384-well plate-based high-throughput platform to identify B-cell
clones expressing FliD-reactive antibodies. Using this approach,
memory B cell clones producing two human monoclonal
antibodies, namely CAA1 and CCG4, were isolated and selected
based on their specificity and affinity for recombinant FliD.
CAA1 was originally isolated as an IgA1 encoded by VH3-48/D2-
15/JH3 with a 21-amino acid HCDR3 and VK1-39/JK5, whereas
CCG4 was isolated as an IgG3 encoded by VH3-9/D1-7/JH1
bearing a shorter 11-amino-acid HCDR3 and VL3-27/JL3.
Generation and Structural Characterization
of FliD-Reactive Recombinant SIgA
Humans present two different IgA subclasses that differ mainly
for the length and glycosylation of the hinge region. IgA1
possesses a 13-amino-acid longer hinge than IgA2 containing up
to five O-linked glycans at serine and threonine residues. The
longer hinge not only confers to IgA1 antibodies higher flexibility
and a longer Fab reach but is also linked to the sensitivity to
a specific class of bacterial proteases known as IgA1 proteases.
Bearing a shorter hinge region lacking proline–serine and/or
proline–threonine peptide bonds, IgA2 is instead resistant to
these proteases (36). In addition, when compared to IgG, IgM,
and IgA1, the IgA2 isotype has the unique characteristic to
undergo reverse transcytosis by contacting Dectin-I receptor on
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the surface of PPs M cells (20). Both the Cα1 region and the
glycosylation pattern appear pivotal for the interaction at the
basis of this mechanism, which has been suggested as a strategy
to boost adaptive immunity against pathogens (37).
The recombinant SIgA1, SIgA2, and dIgA2 versions of the
FliD-reactive mAbs were generated by transient transfection of
Expi293 cells and were then purified by affinity chromatography.
Various physicochemical measurements were performed to
monitor key structural attributes of recombinant FliD-reactive
polymeric IgAs as summarized in Supplemental Figure 3A.
The conformational stability of the mAbs was determined by
monitoring their overall tertiary structure as a function of
temperature (intrinsic tryptophan fluorescence spectroscopy),
and a 6–7◦C lower thermal melting temperature (Tm) value
was observed for SIgA1 when compared to SIgA2 and dIgA2
(Supplemental Figure 3A). The difference in conformational
stability could be due to structural differences in the hinge region
between the two subtypes. The relative solubility of the mAbs was
evaluated by a PEG precipitation assay, and dIgA2 was found to
be relatively more soluble compared to SIgA1 and SIgA2, a result
of which suggests that the presence of the secretory component
protein may affect mAb solubility at neutral pH. Molecular size
analysis by sedimentation velocity analytical ultracentrifugation
(SV-AUC) revealed a heterogeneous distribution of species
for each mAb (Supplemental Figure 3A). We observed that
SIgA2 had a considerably higher relative percent composition
of larger molecular weight species than the other two mAbs
(as compared to the percent main peak). As expected, dIgA2
had a later elution time when compared to SIgA1 and SIgA2
in size exclusion chromatography (Supplemental Figure 3B).
Each of the CAA1 IgA molecules were heavily glycosylated with
carbohydrates ranging from ∼31–39% of the total mass of each
mAb. As expected by sharing the same IgA backbone, the N-
linked oligosaccharide structural types were overall very similar
in SIgA2 and dIgA2 antibodies (Supplemental Figure 3C).
Differently to these antibodies, CAA1 SIgA1 lacked G0F + GN,
G1F – GN, GIF + GN and G1F + NANA, while it contained
G2F2 and Man4G12 + NANA (Supplemental Figure 3C).
Finally, incubation of CAA1 SIgA1 and SIgA2 with recombinant
IgAase from N. gonorrhoeae confirmed the differences in
sensitivity to bacterial IgA proteases of the two isotypes, which
have been associated to the length and sequence of the hinge
regions (Supplemental Figure 3D).
In vitro Characterization of CAA1 and
CCG4 SIgA2
Based on its resistance to bacterial IgA proteases and the ability
to undergo reverse transcytosis, the IgA2 scaffold was initially
selected over the IgA1 for our studies, and both CAA1 and
CCG4 SIgA2 were further characterized in vitro. To include a
control antibody that was not reactive with the antigen in our
experiments of Campylobacter infection, we also generated the
SIgA2 version of the HGN194 mAb, which targets an epitope on
the V3 loop of HIV-1 Env glycoprotein (38).
CAA1 and CCG4 SIgA2 molecules maintained the original
FliD binding activity, displaying similar EC50 (CAA1 = 0.08;
CCG4 = 0.12µg/ml) for the flagellar protein (Figure 1A).
Epitope binning studies by BLI indicated that the binding
of one antibody to the antigen did not prevent the binding
of the other mAb (Figure 1B), pointing to the recognition
of two distinct epitopes. In addition, CAA1, but not CCG4,
recognized FliD by Western blot analysis under denaturing
and reducing conditions, confirming the binding to structurally
different antigenic determinants (Figure 1C). Accessibility of
the two mAbs to these epitopes in the flagellum was
assessed by flow cytometry using two FliD-divergent historical
isolates C. jejuni 81-176 and C. coli NCTC 11437. CAA1
and CCG4 stained both pathogens, thus confirming epitope
accessibility and breadth (Figure 1D). Consistent with FliD
localization, confocal imaging on C. jejuni 81-176 confirmed
that the binding of the two mAbs occurred at the cell poles
(Figure 1E).
Establishing an Immunocompetent Mouse
Model of Campylobacter Infection to Test
the Prophylactic Potential of FliD-Reactive
Antibodies
The murine intestine is highly resistant to Campylobacter due
to intense competition exerted by the rich gut microbiota and
to a certain level of tolerance, which limits inflammation (39–
41). To overcome the challenge represented by the resident
microbiota, pre-treatment via oral gavage with vancomycin,
for which Campylobacter species are inherently resistant (42),
is largely adopted. Although the pretreatment allows robust
bacterial colonization in the cecum, it does not appear to enhance
the pathology in adult wild-type mice since minimal signs of
inflammation were previously observed (31).
Higher susceptibility to C. jejuni infection of infant
wild-type mice in comparison to adult animals has been
previously reported and linked to significant differences
in the microbiota composition (43). To set up a model
that would allow us to evaluate the prophylactic activity
of our mAbs under immunocompetent conditions, we
evaluated the sensitivity to C. jejuni 81-176 infection
of pups (12 days old), weaned (21 days old), and adult
(56 days old) C57BL/6 mice. Animals were pre-treated
with vancomycin via oral gavage to deplete the murine
microbiota before infection with C. jejuni 81-176 at 108
CFU/mouse. Campylobacter isolation from stools at 6 days
post-infection revealed a ∼2 log higher increase in shedding
from 21-day-old animals than from 12- and 56-day-old mice
(Figure 2A). In line with these results, weaned mice displayed
significantly higher intestinal inflammation as measured
by the levels of lipocalin-2 in the stools and histological
score values in the cecum in comparison to pups and adult
mice (Figures 2B,C).
Since antibiotic pretreatment should provide comparable
ecological niches for infection in the different animals, other
factors could be accountable for the different sensitivity to C.
jejuni infection displayed by the three groups of mice. Analysis
of murine IgA in the stools of 12-, 21-, and 56-day-old animals
revealed different concentrations among the groups (Figure 2D).
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FIGURE 1 | In vitro characterization of CAA1 and CCG4 secretory immunoglobulin A (SIgA) binding to FliD. (A) Binding of CAA1, CCG4, and HGN194 SIgA to
recombinant FliD antigen as measure by ELISA. (B) Cross-competition studies performed by biolayer interferometry (BLI). FliD antigen was immobilized on APS
sensors and then incubated with CAA1 prior to association with CCG4, CAA1, or phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA). (C) Western
blot analysis of CAA1, CCG4, and HGN194 SIgA binding to FliD antigen (70 kDa) under reducing and denaturing conditions. (D) Representative histograms of the in
vitro binding of the indicated mAbs against pure culture of C. jejuni 81-176 (ATCC BAA-2151) and C. coli NCTC 11437. A phylogenetic tree built using
neighbor-Joining method with Jukes–Cantor distance measurement is shown to provide the amino acid distance of FliD between the two historical isolates tested (in
red). One representative experiment out of three is represented. (E) Binding of CAA1 SIgA to C. jejuni as observed in confocal microscopy. Bacteria were stained using
Syto BC (green), whereas CAA1 was detected using anti-human IgA AF647 conjugated (red).
Interestingly, weaned mice presented negligible levels of IgA
in the stools in comparison to both pups and adult mice.
This observation is consistent with the transition between the
exogenous supply of maternal antibodies provided along with
the milk (12-day-old mice) and the beginning of the endogenous
production that is established in adult animals (i.e., 56-day-old
mice). Therefore, a likely important factor in the susceptibility
of weaned mice to C. jejuni infection could be the lower
concentration of secretory IgA due to the relative immaturity
of intestinal immune system and the depletion of maternal
antibodies in these animals. Based on these observations, weaned
mice were selected as an immune competent animal model to
study the prophylactic activity of FliD-reactive mAbs.
Since off-target binding of CAA1 and CCG4 to the murine
microbiota would result in reduced bioavailability and thus
activity against pathogens in a prophylactic setting, we evaluated
potential cross-reactivity of the recombinant SIgA with the
microbiota of weaned mice. Stools from animals orally infected
with C. jejuni, C. coli, or PBS (mock infected) were collected
24 h post-infection and incubated with the two FliD-reactive
mAbs and the control HGN194. CCG4 displayed limited levels of
cross-reactivity with the murine microbiota (6.62%), which were
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FIGURE 2 | Superior sensitivity of C5BL/6 just weaned mice to C. jejuni infection. (A–C) C57BL/6 mice at 12, 21, and 56 days of age were orally infected with 108
CFU of C. jejuni. (A) Bacteria loads (CFU) and (B) lipocalin 2 (LCN2) in the stools of infected animals were determined at 6 days postinfection. (C) Representative H&E
sections of the cecum from infected mice and statistical analysis of histopathological scores at 6 days postinfection. White arrows: submucosal inflammation; white
asterisk: crypt hyperplasia with decreased number of goblet cells; black asterisk: epithelial desquamation; black arrows: mucosal inflammation. Scale bar: 200µm.
(D) Quantification of fecal immunoglobulin A (IgA) concentrations in C57BL/6 mice at 12, 21, and 56 days of age. Dots represent individual mice and results are shown
as ±SEM. (A–D) Mann–Whitney test was used. *p < 0.05, **p < 0.01, ***p < 0.001. One representative experiment out of at least two is shown.
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FIGURE 3 | Prophylactic activity of orally administered CAA1 and CCG4 secretory immunoglobulin A (SIgA) against C. jejuni infection in just weaned mice. (A–D) Two
hours prior to infection with 108 CFU of C. jejuni, 21-day-old C57BL/6 mice were orally administered by gavage with 200 µg of the indicated mAbs in
phosphate-buffered saline (PBS). (A) Fecal bacterial load (CFU) at 24, 48, and 72 h post-infection were determined. (B) Lipocalin-2 (LCN2) levels in the stools, (C)
statistical analysis of polymorphonucleated (PMN) cell infiltrates gated as Gr1+CD11b+, and (D) histopathological score in the caecum were determined at 72 h
post-infection in the different treatment conditions. Dots represent individual mice, and results are shown as ±SEM. (A–D) Mann–Whitney test was used. *p < 0.05,
**p < 0.01. One representative experiment out of at least two is shown.
comparable with those observed for the control antibody (1.11%)
(Supplemental Figure 4A). Conversely, CAA1 was binding the
microbiota to a higher extent (22%), suggesting a possible Fab-
mediated recognition of antigens in the commensal bacteria that
present structures similar to FliD (Supplemental Figure 4A).
Nevertheless, for both FliD-reactive mAbs, the percentage of IgA-
coated bacteria dramatically increased in the stools of infected
animals confirming the prompt recognition of the C. jejuni and
C. coli species (CAA1, 79.2 and 73.9%; CCG4, 70.7 and 55.4%).
Interestingly, we also observed an increase in HGN194 binding
to the bacteria in the stools of these animals (26.5 and 26.4%)
that could be consistent with the innate binding activity of IgA
and secretory component against various pathogens (44, 45).
Finally, to examine the conditions for testing the prophylactic
efficacy of the mAbs, we evaluated the pharmacokinetics of orally
administered SIgA in different gastrointestinal tracts of weaned
mice. The Campylobacter-irrelevant HGN194 SIgA2, which
displayed negligible cross-reactivity with the murine microbiota
(Supplemental Figure 4A), was administered as a single oral
gavage of 150 µg in PBS (≈15 mg/kg), and its concentration
in the different intestinal subcompartments was measured at
2, 4, and 8 h post-administration (Supplemental Figure 4B).
HGN194 SIgA concentration in the cecum was maintained
almost constant within the first 4 h post-administration and then
tended to rapidly decrease by 8 h. The human antibody was not
detectable at 12 or 24 h post-administration (data not shown).
Prophylactic Administration of
FliD-Reactive SIgA Accelerates C. jejuni
Clearance and Reduces Intestinal
Inflammation
We next evaluated the prophylactic activity of orally
administered FliD-reactive recombinant SIgA2 in
immunocompetent-weaned mice infected with C. jejuni 81-176.
As such, vancomycin pretreated animals were administered with
a single oral gavage of 200 µg/mouse of CAA1, CCG4, HGN194
SIgA2, or PBS 2 h before oral infection with 108 CFU/mouse
of C. jejuni 81-176. Treated animals and the corresponding
control groups were monitored for 72 h, during which the
severity of infection and degree of inflammation were recorded.
Of note, analysis of the stools from treated mice revealed a
trend characterized by higher Campylobacter shedding at 24 h
post-infection followed by a significant decrease over time.
Conversely, untreated and HGN194-treated groups presented
lower shedding at early time points followed by a consistent CFU
increase at 48 h post-infection (Figure 3A).
These results suggest that that CAA1 and CCG4 could prevent
or reduce the ability of the pathogen to adhere to the surface
of the mucosal epithelium, thus facilitating the clearance of
bacteria via peristalsis or mucociliary activity at early stages post-
infection. This hypothesis is further supported by the significant
lower levels of lipocalin-2, a marker of intestinal inflammation
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linked to epithelial damage and neutrophil infiltration, recorded
at 72 h post-infection in the stools of CAA1- and CCG4-treated
animals in comparison to the control groups (infected/non-
treated and infected/HGN194-treated groups) (Figure 3B). In
addition, animals treated with a single administration of FliD-
reactive mAbs presented levels of PMN cells infiltration and
histological score values in the cecum significantly lower than
the HGN194-treated group (Figures 3C,D), which indicates
that the activity exerted by CAA1 and CCG4 is largely
Fab mediated.
Similar findings were observed in animals administered
2 h before infection with higher or lower Campylobacter
infection doses (107 or 109 CFU/mouse). Indeed, in both
cases CAA1-administered animals presented significantly
higher bacterial clearance than the untreated group
(Supplemental Figures 5A,B) and levels of intestinal
inflammation similar to those of noninfected mice
(Supplemental Figures 5C,D). Furthermore, no significant
differences were observed in the reduction in bacterial
shedding, PMN infiltration in the cecum lamina propria,
and lipocalin-2 levels in the stools when CAA1 SIgA2 was
provided 2 h before infection or when it was premixed with
C. jejuni 81-176 before oral administration to the animals
(Supplemental Figures 5E–G).
Taken together, these results indicate that prophylactic
administration of FliD-specific CAA1 and CCG4 SIgA2 increase
protection from Campylobacter infection by accelerating
bacterial clearance at early stages after infection, thus significantly
reducing inflammation.
IgA Isotype Switch Does Not Affect CAA1
Prophylactic Activity
Since longer Fab reach, higher flexibility, and different
glycosylation may affect the cross-linking ability and/or
persistence of the polymeric Ig in the intestine, we next
investigated whether the two IgA isotypes may exert
different prophylactic activities in our mouse model of
Campylobacter infection.
CAA1 SIgA1 and SIgA2 displayed comparable binding to
FliD (Supplemental Figure 6A), and no significant differences
in reactivity to Campylobacter species in vitro or with murine
microbiota ex vivo were observed between the two formats
(Supplemental Figures 6B,C). The prophylactic activity of the
two isotypes was then tested in the murine model of
Campylobacter infection. In line with our previous findings,
animals administered with the FliD-reactive mAbs displayed
higher Campylobacter shedding at early time postinfection
followed by decrease over time, while infected non-treated
animals produced an opposite trend (Figure 4A).
Although CAA1 SIgA2 accelerated shedding faster than SIgA1
as confirmed also by the percentage of human IgA-coated
bacteria in the stools (Supplemental Figure 6D), both subclasses
were equally capable to limit inflammation in infected animals as
shown by the levels of lipocalin-2 in the stools, PMN infiltration,
and the corresponding histological score in the cecum at 72 h
postinfection (Figures 4B–D).
Overall, our results indicate that differences in flexibility and
glycosylation associated to the two human IgA subclasses do not
have an impact in the prophylactic activity exerted by CAA1 in
the in vivomodel.
SIgA to IgG Conversion Is Detrimental for
CAA1 and CCG4 Prophylactic Activity
Although SIgA are the most abundant antibodies expressed
in association with the intestinal mucosa and the first line of
defense against enteric pathogens, they are characterized by
a complex structure, and their development as drugs might
result challenging in comparison to IgG-based monoclonal
antibodies. Because the activity of the Campylobacter-reactive
mAbs was previously shown to be dependent on the specificity
for FliD, we generated CAA1, CCG4, and the Campylobacter-
irrelevant antibody HGN194 as human IgG1 and evaluated
their prophylactic activity in comparison to their corresponding
SIgA2 counterparts.
Since glycosylation might affect the ability of mAbs to
interact with mucin on the mucosal surface, the localization
and persistence of HGN194 IgG1 in the murine intestinal tract
were appraised by administering the antibody with a single
oral gavage to weaned mice and then by measuring the its
concentration in the different intestinal subcompartments after 2,
4, and 8 h (Supplemental Figure 4C). As in the case of HGN194
SIgA2, at every time point, the highest concentration of the
IgG1 was detected in the cecum; however, in this intestinal
subcompartment, the IgG1 concentration tended to decrease
faster than for SIgA2, with a significant reduction already at 4 h
post-administration (Supplemental Figures 4B,C).
Next, we evaluated the prophylactic activity of the FliD-
reactive mAbs CAA1 and CCG4 as IgG1 or SIgA2 both
administered to weaned mice 2 h before infection with
C. jejuni 81-176. Interestingly, while animals treated with
SIgA2 antibodies displayed the previously observed pattern
characterized by higher shedding at 24 h postinfection
followed by a significant decrease at 48 and 72 h, the groups
treated with the IgG version of the same antibodies revealed
trends similar to the non-treated groups (Figure 5A and
Supplemental Figure 7A). The importance of the SIgA format
for the in vivo efficacy was further confirmed by the lower
ability of CAA1 and CCG4 IgG to limit inflammation in
comparison to their polymeric counterparts, as shown by PMN
cells infiltration in the cecum and lipocalin-2 levels in the stools
of the infected animals at 72 h post-infection (Figures 5B,C
and Supplemental Figures 7B,C). Overall, no significant
differences in the histological scores were observed between
the mice treated with the FliD-reactive IgG antibodies and the
non-treated animals (Figure 5D and Supplemental Figure 7D).
Conversely, the SIgA2 versions of the antibodies were able to
replicate the beneficial effect previously observed, maintaining
the histological score in the cecum to values significantly lower
than both non-treated and IgG-treated mice (Figure 5D and
Supplemental Figure 7D).
Taken together, these data indicate that the CAA1 and CCG4
IgG have limited prophylactic activity when orally administered
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FIGURE 4 | CAA1 SIgA1 and SIgA2 display similar prophylactic activity against C. jejuni infection. (A–D) Two hours prior to infection with 108 CFU of C. jejuni,
21-day-old C57BL/6 mice were orally administered via gavage with 200 µg of CAA1 as SIgA1 or SIgA2. (A) Quantification of the bacterial load (CFU) in the stools of
the animals at 24, 48, and 72 h post-infection. (B) Representative dot plot and relative quantification of polymorphonucleated cells infiltrated in the caecum gated as
Gr1+CD11b+. (C) Quantification of lipocalin-2 (LCN2) in the stools, and (D) statistical analysis of histopathological score in the cecum at 72 h post-infection in the
different treatment conditions. Dots represent individual mice, and results are shown as ±SEM. (A–D) Mann–Whitney test was used. *p < 0.05, **p < 0.01. One
representative experiment out of at least two is shown.
prior to Campylobacter infection. The reduced activity of CAA1
and CCG4 IgG might be dependent on both the lower stability
and persistence in the gastrointestinal tract and/or on the
decreased “bonus effect of multivalency” at the basis of the
cross-linking activity associated with the polymeric format.
DISCUSSION
The aim of this study was to evaluate the ability of orally
administered recombinant SIgA, derived from selected FliD-
reactive monoclonal antibodies, to prevent infections by
Campylobacter species frequently associated with severe
neonatal gastroenteritis.
Despite its pivotal role in bacteria motility, epithelial cells
adherence (25, 33), and the high level of conservation among
C. jejuni (Supplemental Figure 1), FliD has never been assessed
to date as a potential target for therapeutic mAbs. Consistent
with the immunogenicity previously reported for this antigen
(26, 34), our results indicate that FliD-reactive mAbs can be
isolated from the human memory B cell repertoire. Further
development of these antibodies, namely, CAA1 and CCG4,
resulted in recombinant SIgA that preserved the ability to bind
FliD on the Campylobacter’s flagellum of both C. jejuni and C.
coli species (Figure 1D).
Genetically manipulated animals characterized by an
exacerbated inflammatory response to bacteria, such as
SIGIRR or IL10−/−, have been proposed as models to study
Campylobacter pathogenesis (31, 46). These mutations, however,
dramatically alter the murine immune system to an extent
that even the presence of commensal microbes can potentially
Frontiers in Immunology | www.frontiersin.org 12 June 2020 | Volume 11 | Article 1011
Perruzza et al. Prophylactic Activity of Campylobacter-Reactive Recombinant SIgA
FIGURE 5 | Conversion to immunoglobulin G (IgG) reduces CAA1 prophylactic activity against C. jejuni infection. (A–D) Two hours prior to infection with 108 CFU of
C. jejuni, 21-day-old C57BL/6 mice were orally administered via gavage with 200 µg of CAA1 as SIgA2 or IgG1. (A) Quantification of the bacterial load (CFU) in the
stools of the animals at 24, 48, and 72 h post-infection. (B) Representative dot plot and relative quantification of polymorphonucleated cells infiltrated in the cecum
gated as Gr1+CD11b+. (C) Quantification of lipocalin-2 (LCN2) in the stools, and (D) statistical analysis of histopathological score in the cecum at 72 h post-infection
in the different treatment conditions. Dots represent individual mice, and results are shown as ±SEM. (A–D) Mann–Whitney test was used. *p < 0.05, **p < 0.01. One
representative experiment out of at least two is shown.
result in spontaneous enterocolitis (47). The sensitivity of
wild-type mice to Campylobacter infection has consistently been
linked to age-dependent variations in the composition of the
resident microbiota (43). Of note, our findings indicate that
different levels of IgA in the murine intestine also play a role in
Campylobacter pathogenesis in mice. In particular, we observed
that weaned mice represent the most permissive wild-type age
group and that this is likely due to the transition between the
exogenous IgA supply provided by the maternal milk and IgA
endogenous production (Figure 2D). Moreover, Giallourou
et al. described a weaned mouse model of C. jejuni that can
recapitulate enteropathy and diarrhea (48). In the current
study, we established a weaned mouse model of Campylobacter
infection to evaluate the prophylactic activity of the mAbs
based on bacterial shedding and inflammatory biomarkers
(Figures 2A–C). In this animal model, we documented a
consistent effect following a single prophylactic administration
of FliD-reactive SIgA 2 h before C. jejuni infection, which is
characterized by significantly higher Campylobacter shedding
at the early stage of infection followed by a rapid decline at
later time points (Figure 3A). Our hypothesis is that by binding
FliD, the SIgA can limit bacteria motility and ability to adhere
to the surface of the mucosal epithelium, thus accelerating their
clearance via peristalsis. This idea is further strengthened by
the fact that animals administered with FliD-reactive mAbs
display considerably lower levels of inflammatory biomarkers
in the cecum and stools than the control groups, which present
an opposite shedding trend. FliD-reactive mAbs efficacy relies
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on the specific recognition of the bacterial surface antigen, as
an irrelevant antibody in the same format does not produce
similar beneficial effects (Figures 3A–D). Further studies
will elucidate whether these antibodies may act primarily
by limiting bacteria motility (cross-linkage), by limiting
attachment to cell receptors (steric hindrance), by limiting
secretion via the T3SS of proteins that contribute to host cell
invasion (e.g., CiaB) or via a combination of all these activities.
Interestingly, similar prophylactic activity was observed when
CAA1 was premixed with C. jejuni or administered 2 h before
infection, thus confirming SIgA stability during the passage
through the small intestine and their persistence in the cecum
(Supplemental Figures 5E–G).
Despite the fact that SIgA2 showed a slightly higher ability
to accelerate bacterial shedding at early stage of infection in
comparison to the SIgA1 counterpart (Figure 4A), differences
in length and glycosylation of the hinge region between
the two human IgA isotypes do not appear to significantly
undermine the ability of the polymeric immunoglobulins to
prevent inflammation (Figures 4B–D). However, IgA2 might
represent themost promising backbone for development of orally
deliverable mAbs due to resistance to IgA proteases expressed by
different pathogens (Supplemental Figure 3D) and to the unique
ability to undergo reverse transcytosis (20), which in turn could
contribute to boost a potential vaccinal effect (37).
The prophylactic activity of FliD-reactive CAA1 and CCG4
was significantly decreased when these mAbs were administered
as IgG1. Indeed, in the IgG1 format, the mAbs were neither able
to boost Campylobacter shedding at early time postinfection nor
able to limit inflammation to an extent comparable with their
corresponding SIgA (Figure 5 and Supplemental Figure 7). The
superior efficacy of CAA1 and CCG4 as SIgA might be related
to higher resistance to proteases in the small intestine (30, 49),
higher localization and better persistence in the cecum (17, 18),
and/or to themechanisms of action (i.e., cross-linking) associated
with the polymeric immunoglobulin structure (14, 19).
In summary, our results indicate that the flagellar-capping
protein FliD represents a promising target for the development
of Campylobacter-reactive mAbs capable to exert a prophylactic
activity dependent on both their affinity to the antigen and
on features strictly related to the SIgA format. Although
improvement in water sanitation and healthcare conditions
are pivotal to reduce Campylobacter’s impact in infants in
middle- and low-income countries, these findings suggest
that the development of orally deliverable recombinant SIgA
targeting FliD might represent a novel strategy to prevent or
mitigate both disease severity and the development of post-
infection syndromes.
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